The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study

Judit Konya, Thozhukat Sathyapalan, Eric S Kilpatrick, Stephen L Atkin, Judit Konya, Thozhukat Sathyapalan, Eric S Kilpatrick, Stephen L Atkin

Abstract

Objective: Soy and cocoa have been suggested to be beneficial for diabetes. The aim of this study was to identify the effects of soy protein, isoflavones, and cocoa on glycemic control parameters. Research design and methods: The study was a parallel, double-blind, placebo-controlled study where patients with diet or metformin controlled type 2 diabetes were randomized to, casein soy protein with or without isoflavones (SPI, SP), and with or without cocoa (SPIC, SPC) arms for an 8 week period. Glycemic control and cardiovascular risk factors were assessed prior to and after the completion of the dietary intervention. Sixty participants completed the study. Results: Soy protein improved HbA1c compared to casein (p < 0.05). The addition of isoflavones improved indices of insulin resistance and LDL [delta QUICKIE (SPI: -0.12 ± 0.04 vs. SP: 0.03 ± 0.06, p = 0.03); delta LDL (-0.27 ± 0.41 vs. 0.22 ± 0.43, p = 0.02); percentage change in HOMA (31.02 ± 54.75 vs. -14.42 ± 27.07, p = 0.02); percentage change in QUICKIE (-3.89 ± 7.07 vs. 6.11 ± 10.54, p = 0.01)]. However, the addition of cocoa provided no benefit with or without isoflavones. Summary: Soy protein had intrinsic activity on glycemic control compared to casein. Isoflavones improved both insulin resistance and LDL, but cocoa did not have added benefit on these indices. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01754662.

Keywords: cocoa; glycemia control; isoflavones; soy; type 2 diabetes.

References

    1. Federation ID. IDF Diabetes Atlas. 6th ed Kingston upon Hull: (2013).
    1. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. (1990) 120:672–6. 10.1016/0002-8703(90)90026-T
    1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. the Framingham study. JAMA. (1979) 241:2035–8. 10.1001/jama.241.19.2035
    1. Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care. (2001) 24:228–33. 10.2337/diacare.24.2.228
    1. Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab. (1999) 84:3479–84. 10.1210/jc.84.10.3479
    1. Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr. (2001) 131:1202–6. 10.1093/jn/131.4.1202
    1. Tsai AC, Vinik AI, Lasichak A, Lo GS. Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients. Am J Clin Nutr. (1987) 45:596–601. 10.1093/ajcn/45.3.596
    1. Lu MP, Wang R, Song X, Chibbar R, Wang X, Wu L, et al. . Dietary soy isoflavones increase insulin secretion and prevent the development of diabetic cataracts in streptozotocin-induced diabetic rats. Nutr Res. (2008) 28:464–71. 10.1016/j.nutres.2008.03.009
    1. Ascencio C, Torres N, Isoard-Acosta F, Gomez-Perez FJ, Hernandez-Pando R, Tovar AR. Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr. (2004) 134:522–9. 10.1093/jn/134.3.522
    1. Bartke A, Peluso MR, Moretz N, Wright C, Bonkowski M, Winters TA, et al. . Effects of Soy-derived diets on plasma and liver lipids, glucose tolerance, and longevity in normal, long-lived and short-lived mice. Hormone Metab. Res. (2004) 36:550–8. 10.1055/s-2004-825796
    1. Lavigne C, Marette A, Jacques H. Cod and soy proteins compared with casein improve glucose tolerance and insulin sensitivity in rats. Am J Physiol Endocrinol Metabol. (2000) 278:E491–500. 10.1152/ajpendo.2000.278.3.E491
    1. Lee DS, Lee SH. Genistein, a soy isoflavone, is a potent alpha-glucosidase inhibitor. FEBS Lett. (2001) 501:84–6. 10.1016/S0014-5793(01)02631-X
    1. Sorenson RL, Brelje TC, Roth C. Effect of tyrosine kinase inhibitors on islets of Langerhans: evidence for tyrosine kinases in the regulation of insulin secretion. Endocrinology. (1994) 134:1975–8. 10.1210/endo.134.4.8137766
    1. Wagner JD, Cefalu WT, Anthony MS, Litwak KN, Zhang L, Clarkson TB. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism. (1997) 46:698–705. 10.1016/S0026-0495(97)90016-0
    1. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Euro J Clin Nutr. (2003) 57:940–6. 10.1038/sj.ejcn.1601628
    1. Gonzalez S, Jayagopal V, Kilpatrick ES, Chapman T, Atkin SL. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes. Diabetes Care. (2007) 30:1871–3. 10.2337/dc06-1814
    1. Grassi D, Necozione S, Lippi C, Croce G, Valeri L, Pasqualetti P, et al. . Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension. (2005) 46:398–405. 10.1161/01.HYP.0000174990.46027.70
    1. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr. (2005) 81:611–4. 10.1093/ajcn/81.3.611
    1. Grassi D, Desideri G, Necozione S, Lippi C, Casale R, Properzi G, et al. . Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr. (2008) 138:1671–6. 10.1093/jn/138.9.1671
    1. Mellor DD, Sathyapalan T, Kilpatrick ES, Beckett S, Atkin SL. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients. Diabetic Med. (2010) 27:1318–21. 10.1111/j.1464-5491.2010.03108.x
    1. Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, et al. . Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr. (2012) 95:740–51. 10.3945/ajcn.111.023457
    1. Curtis PJ, Sampson M, Potter J, Dhatariya K, Kroon PA, Cassidy A. Chronic ingestion of flavan-3-ols and isoflavones improves insulin sensitivity and lipoprotein status and attenuates estimated 10-year CVD risk in medicated postmenopausal women with type 2 diabetes: a 1-year, double-blind, randomized, controlled trial. Diabetes Care. (2012) 35:226–32. 10.2337/dc11-1443
    1. Mellor DD, Madden LA, Smith KA, Kilpatrick ES, Atkin SL. High-polyphenol chocolate reduces endothelial dysfunction and oxidative stress during acute transient hyperglycaemia in Type 2 diabetes: a pilot randomized controlled trial. Diabetic Med. (2013) 30:478–83. 10.1111/dme.12030
    1. Deckers JG, Schellevis FG, Fleming DM. WHO diagnostic criteria as a validation tool for the diagnosis of diabetes mellitus: a study in five European countries. Eur J Gen Pract. (2006) 12:108–13. 10.1080/13814780600881268
    1. Halm BM, Franke AA, Ashburn LA, Hebshi SM, Wilkens LR. Oral antibiotics decrease urinary isoflavonoid excretion in children after soy consumption. Nutr Cancer. (2008) 60:14–22. 10.1080/01635580701586747
    1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. (1985) 28:412–9. 10.1007/BF00280883
    1. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. . Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. (2000) 85:2402–10. 10.1210/jcem.85.7.6661
    1. Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA, et al. . Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care. (2002) 25:1709–14. 10.2337/diacare.25.10.1709
    1. Kashima H, Uemoto S, Eguchi K, Endo MY, Miura A, Kobayashi T, et al. . Effect of soy protein isolate preload on postprandial glycemic control in healthy humans. Nutrition. (2016) 32:965–9. 10.1016/j.nut.2016.02.014
    1. Li Z, Hong K, Saltsman P, DeShields S, Bellman M, Thames G, et al. . Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein. Euro J Clin Nutr. (2005) 59:411–8. 10.1038/sj.ejcn.1602089
    1. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. (1995) 333:276–82. 10.1056/NEJM199508033330502
    1. Sathyapalan T, Javed Z, Rigby AS, Kilpatrick ES, Atkin SL. Soy protein improves cardiovascular risk in subclinical hypothyroidism: a randomized double-blinded crossover study. J Endocr Soc. (2017) 1:423–30. 10.1210/js.2016-1068
    1. Heiss C, Dejam A, Kleinbongard P, Schewe T, Sies H, Kelm M. Vascular effects of cocoa rich in flavan-3-ols. JAMA. (2003) 290:1030–1. 10.1001/jama.290.8.1030
    1. Konya J. The Influence of Dietary and Other Environmental Changes on Vascular Risk Markers in Type 2 Diabetes. MD thesis.University of Hull; (2014).

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir